Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 07:30 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus...
February 24, 2026 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell...
February 05, 2026 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell...
January 12, 2026 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces 2026 Strategic Priorities

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND...